An Multi-site Prospective Study to Assess the Efficacy and Safety of MMF in the Treatment of Proliferative IgA Nephropathy(IgAN)

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

In order to treat proliferative IgA Nephropathy(IgAN), The investigators designed an open, prospective, randomized parallel study to access the efficacy and safety of MMF compared to corticosteroid .

Patients who fulfill the inclusion criteria will be randomized in a 1:1 ratio to either the MMF group or corticosteroid group.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Zhi-Hong Liu, M.D.
• Treatments: Mycophenolate mofetil; Mycophenolic Acid; Prednisone

Criteria

Inclusion Criteria:

1. Patients who signed written informed consent form

2. age between 18-60 years, female or male

3. diagnosed IgA Nephropathy (IgAN) by renal biopsy during 1 months

4. renal biopsy had: 10%< crescents<50%; endocapillary hypercellularity; or necrosis ,and interstitial fibrosis<50%,

5. proteinuria>1g/24h for two times

Exclusion Criteria:

1. secondary IgA Nephropathy (IgAN);

2. eGFR<30ml/min/1.73m2.( MDRD formula)

3. liver disfunction;

4. uncontrolled hypertension

5. WBC <3000/mm3

6. Severe viral infection(HBV, HCV, CMV) within 3 months ofor known HIV infection.

7. diabetes or obesity(BMI>28) ;

8. severe infection or central nervous system symptoms.